Understanding the mode of action of PDAC targeted drugs (P18)

点击翻译按钮获取中文摘要

We will apply our newly developed proteomic technology termed decryptM that characterizes the effects of mutant KRAS targeted drugs on the proteome and phospho-proteome of cellular and animal models of PDAC in a fully time- and dose-dependent fashion. Covering 10,000 proteins, 20,000 phosphorylation sites, 2,000 acetylation sites and 5,000 ubiquitinylation sites in parallel will yield unprecedented pharmacodynamic information regarding drug target engagement, distinguish the main mechanism of action (MoA) from lesser drug effects, and shed light on drug adaptation or resistance mechanisms.